NTQ5082: A Comprehensive Clinical and Pharmacological Profile of a Novel Complement Factor B Inhibitor

Executive Summary

This report provides a comprehensive analysis of NTQ5082, an investigational, orally administered small molecule medication developed by Nanjing Chia Tai Tianqing Pharmaceutical. NTQ5082 is a potent and specific inhibitor of Complement Factor B (CFB), a critical enzyme in the alternative pathway of the complement system. By targeting CFB, NTQ5082 is designed to modulate the dysregulated immune activity that underpins a range of severe hematological and renal diseases.

The clinical development program for NTQ5082 is robust and strategically focused on two primary therapeutic areas. The lead indication is Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare and life-threatening blood disorder. The PNH program has advanced to a pivotal Phase III clinical trial (NCT07177859), which is designed as a head-to-head, active-controlled study against Eculizumab, the established intravenous standard of care. This ambitious trial design, coupled with a long-term safety and efficacy extension study (NCT07177872), signals a clear intent to establish NTQ5082 as a competitive, patient-friendly alternative in the PNH treatment landscape.

Concurrently, NTQ5082 is being developed for complement-mediated renal disorders, with Primary IgA Nephropathy (IgAN) as the secondary lead indication. A multicenter, randomized, placebo-controlled Phase II trial (NCT06982040) is underway to evaluate multiple dose levels in patients with persistent proteinuria, a key marker of disease progression. The broader development pipeline also includes early-phase investigations into other rare conditions such as Atypical Hemolytic Uremic Syndrome (aHUS), C3 glomerulopathy, and Cold Agglutinin Disease, underscoring a "pipeline-in-a-pill" strategy to maximize the therapeutic potential of the asset.

A key differentiating feature of NTQ5082 is its formulation as an oral capsule, which represents a significant potential improvement in treatment convenience and quality of life compared to the infusion-based biologic therapies that currently dominate the complement inhibitor market. However, as with other inhibitors of the complement system, the safety profile of NTQ5082 is characterized by a class-specific risk of serious infections with encapsulated bacteria. Consequently, stringent risk mitigation protocols, including mandatory vaccination against meningococcal and pneumococcal pathogens, are integral to its clinical development and will be a critical component of its potential future use.

Overall, NTQ5082 emerges as a promising therapeutic candidate with a well-defined mechanism of action and a comprehensive clinical program. The outcomes of the ongoing pivotal trials in PNH and IgAN will be critical determinants of its future role in treating complement-driven diseases.

Pharmacological Profile and Mechanism of Action

Molecular and Pharmacological Classification

NTQ5082 is classified as a small molecule drug and is designated as a New Molecular Entity (NME).[1] This classification is fundamentally important as it distinguishes NTQ5082 from the large-molecule biologic therapies, such as monoclonal antibodies, that have historically dominated the field of complement inhibition. As a small molecule, NTQ5082 possesses physicochemical properties that permit oral administration via a capsule formulation, a feature consistently highlighted across its clinical trial protocols.[2] Pharmacologically, it is categorized as an antianaemic agent, reflecting its primary development focus in PNH, and its therapeutic applications span Immune System Diseases, Hemic and Lymphatic Diseases, and Urogenital Diseases.[1]

The development of an oral small molecule represents a significant strategic endeavor in this therapeutic space. The current standards of care, including the active comparator Eculizumab, are administered via intravenous infusion, which imposes a substantial treatment burden on patients, requiring regular travel to infusion centers and lengthy administration times. An effective oral therapy like NTQ5082 offers the potential for a paradigm shift in patient management, enhancing autonomy, reducing healthcare system resource utilization, and potentially improving long-term treatment adherence and quality of life. Should NTQ5082 demonstrate a favorable efficacy and safety profile comparable to existing therapies, its oral route of administration alone could position it as a highly competitive and preferred treatment option for both patients and clinicians.

The Alternative Complement Pathway: Rationale for Therapeutic Intervention

The complement system is a crucial component of the innate immune system, comprising a network of plasma proteins that act in a cascading fashion to eliminate pathogens and damaged cells. It can be activated through three main pathways: the classical, lectin, and alternative pathways. The alternative pathway (AP) functions as a powerful amplification loop for all three pathways and is subject to continuous, low-level spontaneous activation. In healthy individuals, host cells are protected from AP-mediated damage by a suite of membrane-bound and soluble regulatory proteins.

However, in several pathological conditions, dysregulation or over-activation of the AP is a central driver of tissue damage and disease. In PNH, the absence of GPI-anchored complement regulators (CD55 and CD59) on the surface of hematopoietic cells leaves them vulnerable to destruction by the complement system, with the AP amplification loop playing a key role in driving intravascular hemolysis. In renal diseases like IgAN and C3 glomerulopathy, inappropriate deposition and activation of complement components within the kidney's glomeruli, again driven by the AP, leads to chronic inflammation, proteinuria, and progressive loss of renal function.[4]

Complement Factor B (CFB) is an essential zymogen and serine protease of the alternative pathway. Upon activation, CFB is cleaved by Complement Factor D to form the Bb fragment, which then combines with C3b to form the AP C3 convertase (C3bBb). This enzyme complex is the core of the amplification loop, as it can cleave thousands of C3 molecules, leading to exponential activation of the complement cascade. Therefore, inhibiting the enzymatic activity of CFB is a highly strategic therapeutic approach, as it targets the AP at its critical amplification step, effectively shutting down the downstream pathological consequences of its over-activation.[4]

NTQ5082: Mechanism of Complement Factor B (CFB) Inhibition

NTQ5082 is explicitly and consistently identified as a Complement Factor B (CFB) inhibitor.[2] Its mechanism of action involves the direct inhibition of the enzymatic activity of CFB. By binding to CFB, NTQ5082 prevents its proper function within the complement cascade, thereby blocking the formation and activity of the alternative pathway C3 convertase.[4] This upstream inhibition effectively quenches the AP amplification loop, preventing the generation of downstream effectors such as the anaphylatoxin C3a, the opsonin C3b, and the terminal membrane attack complex (MAC). This precise mechanism provides a strong scientific rationale for its investigation in diseases where AP dysregulation is a primary pathophysiological driver.

Developer Profile: Nanjing Chia Tai Tianqing Pharmaceutical

The originator organization and sponsor for the entire clinical development program of NTQ5082 is Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., a major Chinese pharmaceutical company.[1] The company is responsible for all identified clinical trials, positioning NTQ5082 as a key internally developed asset.

---

Table 1: Summary of NTQ5082 Clinical Trial Portfolio

Trial ID	Phase	Indication(s)	Status	Study Design	Planned Enrollment	Key Intervention(s)
NCT07177859	3	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Not Yet Recruiting	Randomized, Open-Label, Active-Controlled	78	NTQ5082 200 mg qd; Eculizumab
NCT07177872	3	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Not Yet Recruiting	Open-Label, Single-Group	78	NTQ5082 200 mg
NCT06764303	2	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Active, Not Recruiting	Randomized, Open-Label	24	NTQ5082 100 mg qd; NTQ5082 200 mg qd
NCT06982040	2	Primary IgA Nephropathy (IgAN)	Not Yet Recruiting	Randomized, Double-Blind, Placebo-Controlled	80	NTQ5082 100/200/300 mg; Placebo
CTR20252008	1	Healthy Subjects	Completed	N/A	N/A	[14C] NTQ5082
Various	1	Atypical Hemolytic Uremic Syndrome	Phase 1	N/A	N/A	NTQ5082
Various	1	Cold Agglutinin Disease	Phase 1	N/A	N/A	NTQ5082
Various	IND Approval	C3 glomerulopathy	IND Approval	N/A	N/A	NTQ5082
Data compiled from sources:.2

---

Clinical Development Program in Paroxysmal Nocturnal Hemoglobinuria (PNH)

The clinical development of NTQ5082 in PNH is the most advanced component of its portfolio, progressing from early dose-finding studies to a large-scale, pivotal Phase III program. The program is systematically designed to establish efficacy, define the optimal dose, and characterize the long-term safety profile of the drug in this patient population.

Phase II Dose-Finding and Efficacy Assessment (NCT06764303)

The foundation of the late-stage PNH program is a multicenter, randomized, open-label Phase II clinical trial (ID: NCT06764303, also NTQ5082-201).[8] The primary objective of this study was to evaluate the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NTQ5082 capsules in patients with PNH.[2]

The trial was designed to enroll an estimated 24 PNH patients who were complement inhibitor-naïve.[8] Participants were randomized into two parallel dosing cohorts to receive either NTQ5082 100 mg once daily (qd) or 200 mg qd.[2] This design is characteristic of a dose-ranging study intended to identify the most appropriate dose to carry forward into pivotal trials by balancing efficacy signals with the safety and tolerability profile. Key inclusion criteria targeted patients with clinically significant disease, requiring evidence of active intravascular hemolysis (lactate dehydrogenase levels >1.5 times the upper limit of normal [ULN]) and significant anemia (hemoglobin <100 g/L).[2]

Pivotal Phase III Trial Design: Head-to-Head Evaluation Against Eculizumab (NCT07177859)

Building upon the Phase II findings, Nanjing Chia Tai Tianqing Pharmaceutical has designed a pivotal Phase III study (ID: NCT07177859) that represents a confident and aggressive step towards market registration.[3] This is a multicenter, randomized, open-label, active-controlled trial designed to directly compare the efficacy and safety of NTQ5082 with Eculizumab, an established intravenous C5 inhibitor and a global standard of care for PNH.[3]

The decision to conduct a head-to-head trial against the market leader, rather than a placebo-controlled study, is a high-risk, high-reward strategy. While a placebo-controlled trial is often a more straightforward path to demonstrating efficacy, it may be ethically complex in a condition with an effective approved therapy and provides limited information on the drug's relative performance. By choosing an active comparator, the sponsor aims to generate data that could establish NTQ5082 as non-inferior or potentially superior to Eculizumab. A successful outcome would provide powerful evidence for physicians, payers, and regulatory bodies, greatly facilitating market access and adoption, particularly when combined with the convenience of oral administration.

The trial plans to enroll approximately 78 subjects, randomized in a 2:1 ratio to one of two arms [3]:

• Experimental Arm: 52 subjects will receive NTQ5082 capsules at a dose of 200 mg once daily.[3] The selection of the 200 mg dose for this pivotal trial strongly suggests that the results of the Phase II study (NCT06764303) identified this dose as providing the optimal risk-benefit profile compared to the 100 mg dose.
• Active Comparator Arm: 26 subjects will receive Eculizumab injection according to its standard dosing regimen.[3]

The trial's primary efficacy endpoint is rigorously defined: the proportion of subjects achieving a hemoglobin (HB) level of ≥120 g/L on at least three of four measurements conducted between Weeks 18 and 24, all in the absence of red blood cell (RBC) transfusions after the second week of treatment.[3] A key secondary endpoint measures the proportion of subjects who achieve a clinically meaningful increase in hemoglobin of

≥20 g/L from baseline during the same period, also without transfusions.[3] These endpoints are clinically relevant, focusing on both normalization of hemoglobin and transfusion independence, which are primary goals of PNH therapy.

Long-Term Efficacy and Safety Extension Study Protocol (NCT07177872)

To complement the pivotal trial and gather essential long-term data, a multicenter, open-label, single-group extension study has been planned (ID: NCT07177872, also NTQ5082-PNH-302).[7] This study is designed to evaluate the long-term efficacy and safety of NTQ5082 in patients who have completed a prior NTQ5082 trial.[7]

The study will enroll an estimated 78 participants, including those who received NTQ5082 in the parent trials as well as those from the Eculizumab control group who will be switched to NTQ5082.[7] All participants in this extension study will receive NTQ5082 capsules at a dose of 200 mg.[7] The primary purpose is to assess durability of response and monitor for any cumulative or late-onset toxicities over an extended period. Key outcome measures will be assessed over a 96-week timeframe and include the proportion of subjects maintaining a hemoglobin level of

≥120 g/L without transfusions and the overall change in hemoglobin levels from pre-treatment baseline.[11] This study is critical for building a comprehensive safety database required for regulatory approval and for providing clinicians with confidence in the drug's long-term use.

---

Table 2: Comparative Analysis of PNH Phase II and Phase III Trial Designs

Feature	Phase II Trial (NCT06764303)	Pivotal Phase III Trial (NCT07177859)
Primary Objective	Evaluate efficacy, safety, and PK/PD; dose-finding	Evaluate efficacy and safety vs. active comparator
Design	Randomized, Open-Label	Randomized, Open-Label, Active-Controlled
Dosing Arms	NTQ5082 100 mg qd NTQ5082 200 mg qd	NTQ5082 200 mg qd
Comparator	No comparator (internal dose comparison)	Eculizumab Injection
Primary Endpoint	Not specified, likely related to hemolysis/hemoglobin	Proportion of subjects with HB ≥120 g/L without RBC transfusions (Wks 18-24)
Key Population	Complement inhibitor-naïve PNH patients	PNH patients (details on prior treatment not fully specified)
Data compiled from sources:.2

---

Clinical Development in Complement-Mediated Renal Disorders

Recognizing that the mechanism of CFB inhibition has therapeutic relevance beyond hematology, Nanjing Chia Tai Tianqing is pursuing a parallel development strategy in complement-mediated renal diseases. This "pipeline-in-a-pill" approach leverages a single molecular entity to address multiple rare diseases, diversifying risk and maximizing the potential value of the asset.

Rationale for CFB Inhibition in Primary IgA Nephropathy (IgAN)

Primary IgA Nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage renal failure. While the disease is initiated by the deposition of galactose-deficient IgA1-containing immune complexes in the glomerular mesangium, a growing body of evidence indicates that the alternative complement pathway is a key mediator of the subsequent kidney inflammation and damage. The deposited immune complexes are thought to trigger local AP activation, leading to glomerular injury, proteinuria, and a progressive decline in renal function. Consequently, inhibiting the AP amplification loop via a CFB inhibitor like NTQ5082 is a highly promising and mechanistically rational therapeutic strategy aimed at reducing proteinuria and preserving long-term kidney function in patients with IgAN.[4]

Phase II Placebo-Controlled Trial Design and Endpoints in IgAN (NCT06982040)

To investigate this hypothesis, a robust Phase II clinical trial has been designed (ID: NCT06982040, also NTQ5082-202).[6] This is a multicenter, randomized, double-blind, placebo-controlled study intended to rigorously evaluate the efficacy and safety of NTQ5082 in patients with Primary IgAN.[6] The quadruple-masking (participant, care provider, investigator, outcomes assessor) design is the gold standard for minimizing bias in clinical research.[6]

The trial plans to enroll an estimated 80 patients and employs a dose-ranging, parallel-assignment model with four distinct arms [6]:

• Experimental Arm 1: NTQ5082 capsules 100 mg
• Experimental Arm 2: NTQ5082 capsules 200 mg
• Experimental Arm 3: NTQ5082 capsules 300 mg
• Placebo Comparator Arm: Placebo capsules

The study's eligibility criteria are designed to select a patient population at high risk of disease progression who have an unmet medical need. Key inclusion criteria include a biopsy-confirmed diagnosis of IgAN and persistent proteinuria (24-hour urine protein excretion [24h-UPE] ≥0.75 g/24h) despite receiving a stable and maximized dose of standard-of-care therapy with a renin-angiotensin system (RAS) inhibitor for at least 12 weeks prior to randomization.[4]

The primary efficacy endpoint is the log-transformed ratio of the 24-hour urine protein-to-creatinine ratio (24h-UPCR) compared to baseline after 12 weeks of treatment.[6] Reduction in proteinuria is a well-established surrogate endpoint in IgAN trials that is considered by regulatory agencies to be reasonably likely to predict long-term clinical benefit in terms of preserving kidney function. Success in this trial could pave the way for a pivotal Phase III study and potentially an accelerated approval pathway.

Emerging Indications

The development scope for NTQ5082 extends to a portfolio of other rare, complement-mediated diseases, indicating a broad and ambitious long-term strategy. The highest development phases for these additional indications are currently in early stages [5]:

• Atypical Hemolytic Uremic Syndrome (aHUS): Phase 1
• Cold Agglutinin Disease: Phase 1
• C3 glomerulopathy (C3G): Investigational New Drug (IND) Approval
• Idiopathic Thrombocytopenic Purpura (ITP): Phase 1
• Hemolysis: Phase 1

This diverse pipeline highlights the sponsor's commitment to fully exploring the therapeutic potential of CFB inhibition across a spectrum of diseases where the alternative complement pathway is implicated.

Comprehensive Safety and Tolerability Analysis

Integrated Analysis of Eligibility Criteria Across Clinical Programs

An integrated analysis of the exclusion criteria across the PNH and IgAN clinical trial protocols provides a preliminary but consistent picture of the anticipated safety profile and patient populations for whom NTQ5082 may be contraindicated. Several key exclusions appear consistently across programs, reflecting general safety precautions for an investigational agent as well as concerns specific to its mechanism of action.

Common exclusion criteria include:

• Prior Transplantation: A history of bone marrow/hematopoietic stem cell or solid organ transplantation is a consistent exclusion, likely due to the confounding effects of immunosuppressive regimens and the potential for altered drug pharmacology or heightened infection risk in this population.[2]
• Recent Malignancy: Patients with a history of malignant tumors within the past 5 years are generally excluded, with standard exceptions for certain cured, low-risk cancers such as localized basal cell carcinoma of the skin or cervical carcinoma in situ.[2]
• Immunodeficiency: Individuals with known or suspected hereditary complement deficiencies or other primary or severe secondary immunodeficiencies are excluded. Administering a potent complement inhibitor to such patients could pose an unacceptable risk of overwhelming infection.[2]
• Active or Recent Infection: A history of active systemic bacterial, viral, or fungal infection within 14 days of the first drug dose is an exclusion criterion, as is a history of recurrent invasive infections with encapsulated bacteria.[2]
• Vaccination Status: Receipt of any live attenuated vaccine within the 4 weeks prior to screening is prohibited.[2]
• Pregnancy and Lactation: Pregnant or lactating females are consistently excluded from all trials.[4]

Class-Specific Safety Considerations: Management of Infection Risk

The most significant safety concern associated with the inhibition of the complement system is an increased susceptibility to certain infections, particularly those caused by encapsulated bacteria. The alternative complement pathway plays a vital role in the opsonization and clearance of pathogens like Neisseria meningitidis (meningococcus) and Streptococcus pneumoniae (pneumococcus). By design, NTQ5082 potently inhibits this pathway, thereby creating a state of increased vulnerability to these specific microorganisms.

This risk is not merely theoretical; it is a well-established class effect for complement-inhibiting drugs. The clinical development program for NTQ5082 directly addresses this risk with a stringent and non-negotiable risk mitigation strategy. Every clinical trial protocol, across all indications, mandates that participants must be vaccinated against ACYW135 meningococcal serogroups and pneumococcal bacteria.[2] These vaccinations must be administered at least 14 days prior to the first dose of the study drug to allow for an adequate immune response. In cases where vaccination occurs within this 14-day window, prophylactic antibiotic treatment is required until the 14-day post-vaccination period is complete.[2] This mandatory vaccination protocol is a direct consequence of the drug's mechanism of action and will undoubtedly be a cornerstone of its risk evaluation and mitigation strategy (REMS) if approved, likely carrying a boxed warning on its label.

---

Table 3: Comparison of Patient Eligibility Criteria for PNH and IgAN Programs

Criteria Category	PNH Program (NCT07177859)	IgAN Program (NCT06982040)
Disease Diagnosis	Diagnosis of PNH with PNH clone size >10%	Biopsy-confirmed Primary IgA Nephropathy
Key Biomarkers	Evidence of active hemolysis (e.g., LDH >1.5x ULN)	24h-UPE ≥0.75 g/24h or UPCR ≥0.8 g/g
Hematological Status	Anemia (e.g., HB <100 g/L); No evidence of severe bone marrow failure (e.g., ANC <0.5×10⁹/L)	Not a primary criterion
Renal Function	No severe kidney disease (e.g., eGFR ≥30 mL/min/1.73m²)	eGFR ≥30 mL/min/1.73m²
Required Prior/Stable Treatment	Stable doses of iron, corticosteroids (≤15 mg/day prednisone equivalent), etc.	Stable, maximized dose of RAS inhibitor for ≥12 weeks
Key Exclusions	History of splenectomy	Renal pathology showing >50% glomerular crescents or severe fibrosis
Data compiled from sources:.2

---

Strategic Assessment and Future Outlook

Competitive Landscape in Complement Inhibition

NTQ5082 is poised to enter a dynamic and increasingly competitive therapeutic landscape. In its lead indication of PNH, the primary benchmark and direct competitor is Eculizumab, the first-generation C5 inhibitor against which NTQ5082 is being tested directly.[3] The market also includes second-generation, longer-acting C5 inhibitors like Ravulizumab, which offer less frequent dosing. The key competitive advantage for NTQ5082 against these established intravenous therapies is its oral route of administration.

However, the field of oral complement inhibitors is also evolving. Other companies are developing oral agents that target different points in the cascade, such as Factor D inhibitors or C3 inhibitors. Notably, the oral Factor B inhibitor Iptacopan (Fabhalta) was recently approved by the FDA for PNH and is also approved for C3G and IgAN, making it a direct mechanistic and commercial competitor.[12] Therefore, the success of NTQ5082 will depend not only on demonstrating non-inferiority to infused therapies but also on differentiating itself from other emerging oral agents in terms of efficacy, safety, and dosing convenience.

Developmental Trajectory and Potential Regulatory Pathways

The clinical development program for NTQ5082 demonstrates a clear and logical progression. PNH is firmly established as the lead indication, with a comprehensive Phase III program designed to support a registrational filing for full approval.[5] The active-controlled design of NCT07177859, combined with the long-term data from NCT07177872, should provide a robust data package for submission to global regulatory authorities.

For the IgAN program, the use of proteinuria reduction as a primary endpoint in the Phase II trial aligns with current regulatory thinking.[6] Positive results from this study could support advancement to a pivotal Phase III trial, which may also use a proteinuria-based surrogate endpoint to seek accelerated approval. This pathway has been successfully utilized by other drugs in the IgAN space and could significantly shorten the time to market for this indication. The portfolio of earlier-stage indications provides a long-term strategic roadmap for life-cycle management and market expansion, contingent on the success of the lead programs.

The aggressive and methodologically rigorous clinical development program, particularly the decision to conduct a head-to-head trial against a global standard of care, reflects a significant strategic ambition. This approach suggests that Nanjing Chia Tai Tianqing Pharmaceutical is not merely focused on the domestic Chinese market but is generating data of a quality and relevance sufficient for submission to major international regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This positions NTQ5082 as a potential global product and signals the company's evolution into a developer of innovative medicines for the world market.

Key Unanswered Questions and Recommendations for Future Monitoring

While the available information outlines a promising and well-designed program, several critical questions remain unanswered. The resolution of these points will be crucial for a complete assessment of NTQ5082's potential.

1. Clinical Trial Data: The most significant unknown is the actual clinical data. The results from the completed Phase I material balance study (CTR20252008) and, more importantly, the top-line efficacy and safety data from the Phase II dose-ranging study in PNH (NCT06764303) are not yet public. This data was foundational to the decision to advance the 200 mg dose into Phase III and would provide the first clinical validation of the drug's efficacy.
2. Comprehensive Safety Profile: Beyond the anticipated risk of encapsulated bacterial infections, the full adverse event profile of NTQ5082 remains to be characterized. Long-term data will be needed to assess for any potential off-target effects, cumulative toxicities, or other safety signals that may emerge with chronic dosing.
3. Pharmacokinetic and Pharmacodynamic Profile: While the Phase II PNH study aimed to assess PK/PD characteristics, detailed information on the drug's absorption, distribution, metabolism, and excretion, as well as the dose-response relationship with biomarkers of complement inhibition, is not yet available.
4. Global Commercial Strategy: The sponsor's plans for development, registration, and commercialization outside of China are not yet clear. Strategies for pricing, market access, and potential partnerships in North America and Europe will be critical to the drug's global success.

For stakeholders, including investors, clinicians, and potential partners, the most critical upcoming catalysts will be the data readouts from the pivotal Phase III trial in PNH (NCT07177859) and the Phase II trial in IgAN (NCT06982040). These two trials represent the primary value inflection points for the NTQ5082 program and will ultimately determine its therapeutic and commercial future. Close monitoring of communications from Nanjing Chia Tai Tianqing Pharmaceutical regarding the progress and results of these studies is strongly recommended.

Works cited

1. NTQ 5082 - AdisInsight - Springer, accessed September 26, 2025, https://adisinsight.springer.com/drugs/800079506
2. A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients - ClinicalTrials.Veeva, accessed September 26, 2025, https://ctv.veeva.com/study/a-study-of-ntq5082-capsules-in-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria-patients
3. NCT07177859 | A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients | ClinicalTrials.gov, accessed September 26, 2025, https://clinicaltrials.gov/study/NCT07177859
4. Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | MedPath, accessed September 26, 2025, https://trial.medpath.com/clinical-trial/f67e3155f8d66e96/nct06982040-ntq5082-capsules-primary-iga-nephropathy
5. NTQ5082 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 26, 2025, https://synapse.patsnap.com/drug/641c64ab49854c40bb299ae316a1df65
6. Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | ClinicalTrials.gov, accessed September 26, 2025, https://clinicaltrials.gov/ct2/show/NCT06982040
7. A Long-term Efficacy and Safety of NTQ5082 Capsules - ClinicalTrials.Veeva, accessed September 26, 2025, https://ctv.veeva.com/study/a-long-term-efficacy-and-safety-of-ntq5082-capsules
8. A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients | Clinical Research Trial Listing - CenterWatch, accessed September 26, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06764303/a-study-of-ntq5082-capsules-in-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria-patients?activelyRecruiting=false&page=123&id=373&slug=anemia
9. A Multicenter, Randomized, Open-label, Active-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria - AdisInsight, accessed September 26, 2025, https://adisinsight.springer.com/trials/700386547
10. NTQ5082 capsules 200 mg in Paroxysmal Nocturnal Hemoglobinuria - Clinical Trials Registry - ICH GCP, accessed September 26, 2025, https://ichgcp.net/amp/clinical-trials-registry/NCT07177872
11. Study Details | NCT07177872 | A Long-term Efficacy and Safety of NTQ5082 Capsules, accessed September 26, 2025, https://clinicaltrials.gov/study/NCT07177872
12. FDA approves first treatment for adults with complement 3 glomerulopathy, a rare kidney disease, to reduce proteinuria, accessed September 26, 2025, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-adults-complement-3-glomerulopathy-rare-kidney-disease-reduce